Sobi to temporarily withdraw New Drug Application for Orfadin(R) oral suspension in the US
December 27, 2013 02:08 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Dec. 27, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) announced today its decision to withdraw the company's New Drug Application for an oral suspension of...
Sobi to take direct responsibility for Orfadin in the US, Canada and Latin America
December 20, 2013 06:09 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has decided to take direct responsibility for Orfadin® in the US,...
Sobi's partner Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX(TM)
December 02, 2013 07:33 ET
|
Swedish Orphan Biovitrum AB (publ)
Stockholm, Sweden, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has extended the...
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
November 29, 2013 03:01 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Nov. 29, 2013 (GLOBE NEWSWIRE) -- The total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi) as per 29 November 2013 amounts to 270,389,770 shares, all common shares,...
Sobi awarded Best Biotech Pipeline at World Orphan Drug Congress
November 21, 2013 02:32 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Nov. 21, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB (publ) (Sobi) has been awarded Best Biotech Pipeline
at the World Orphan Drug Congress in Geneva. The award recognises...
Sobi receives approval for Kineret(r) for treatment of rare disease CAPS
November 20, 2013 02:03 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Nov. 20, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the European
Commission (EC) has approved Kineret (anakinra) for the treatment of...
Sobi's partner Biogen Idec expects mid-2014 US launch of ELOCTATE(r)
November 12, 2013 12:39 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Nov. 12, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB's (publ) (Sobi) partner Biogen Idec today, at the
Credit Suisse Global Healthcare Conference in Phoenix, stated that...
Sobi hosts Capital Market Day event - announces phase I Complement Inhibitor program
November 05, 2013 02:03 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Nov. 5, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a
novel investigational biopharmaceutical drug candidate, SOBI002, into...
Sobi submits application for Orfadin(R) oral suspension to FDA
October 29, 2013 03:07 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden, Oct. 29, 2013 (GLOBE NEWSWIRE) --
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's
application for Orfadin oral suspension has been submitted to the US...
Sobi gains rights to distribute RAVICTI(R) on a named patient use basis in Middle East from Hyperion Therapeutics, Inc.
October 01, 2013 02:06 ET
|
Swedish Orphan Biovitrum AB (publ)
STOCKHOLM, Sweden and SOUTH SAN FRANCISCO, Calif., Oct. 1, 2013 (GLOBE NEWSWIRE) --
Swedish
Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Hyperion Therapeutics, Inc.,
(NASDAQ: HPTX) announced...